Matthew Segall is an accomplished CEO and former academic with expertise in computation, physics, and molecular modeling. He holds an MSc in Computation from the University of Oxford and a PhD in Physics from the University of Cambridge. Segall has held senior positions at a number of reputable organizations, including BioFocus DPI, Inpharmatica Ltd, and ArQule. Throughout his career, he has excelled in the development of innovative drug discovery technologies and has published numerous research articles on molecular simulation and drug design. In addition to his many professional achievements, he is also a former postdoctoral researcher at the illustrious Cavendish Laboratory at the University of Cambridge.